Enanta Pharmaceuticals, Inc.
ENTA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $15,125 | $18,314 | $14,926 | $16,959 |
| % Growth | -17.4% | 22.7% | -12% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $15,125 | $18,314 | $14,926 | $16,959 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $23,809 | $27,210 | $28,065 | $27,656 |
| G&A Expenses | $9,702 | $9,997 | $11,388 | $12,846 |
| SG&A Expenses | $9,702 | $9,997 | $11,388 | $12,846 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $33,511 | $37,207 | $39,453 | $40,502 |
| Operating Income | -$18,386 | -$18,893 | -$24,527 | -$23,543 |
| % Margin | -121.6% | -103.2% | -164.3% | -138.8% |
| Other Income/Exp. Net | -$282 | $667 | $578 | $837 |
| Pre-Tax Income | -$18,668 | -$18,226 | -$23,949 | -$22,706 |
| Tax Expense | $32 | $29 | -$1,305 | -$416 |
| Net Income | -$18,700 | -$18,255 | -$22,644 | -$22,290 |
| % Margin | -123.6% | -99.7% | -151.7% | -131.4% |
| EPS | -0.87 | -0.85 | -1.06 | -1.05 |
| % Growth | -2.4% | 19.8% | -1% | – |
| EPS Diluted | -0.87 | -0.85 | -1.06 | -1.05 |
| Weighted Avg Shares Out | 21,380 | 21,322 | 21,355 | 21,238 |
| Weighted Avg Shares Out Dil | 21,380 | 21,322 | 21,355 | 21,238 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,105 | $2,285 | $2,292 | $2,799 |
| Interest Expense | $2,387 | $1,618 | $1,714 | $1,962 |
| Depreciation & Amortization | $0 | $1,210 | $1,203 | $889 |
| EBITDA | -$16,281 | -$15,398 | -$21,032 | -$19,855 |
| % Margin | -107.6% | -84.1% | -140.9% | -117.1% |